Abstract
Suicide gene therapy using the herpes simplex virus thymidine kinase (HSV-tk) gene, combined with the prodrug ganciclovir (GCV) medication, is a promising approach for the treatment of malignant tumors, including prostate cancer. The success of this therapeutic strategy requires tissue- or tumor-specific gene expression and efficient gene delivery. In this chapter, we describe the experimental protocols of key methodologies, including promoter construction, reporter assay, adenoviral vector construction and preparation, HSV-tk enzymatic assay and cytotoxicity assay to evaluate the specificity and efficacy of osteonectin promoter-mediated HSV-tk/GCV suicide gene therapy of prostate cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, Goncalves F (2017) Bone metastases: an overview. Oncol Rev 11(1):321
Muralidharan A, Smith MT (2013) Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. Inflammopharmacology 21(5):339–363
Sung SY, Chang JL, Chen KC, Yeh SD, Liu YR, Su YH, Hsueh CY, Chung LW, Hsieh CL (2016) Co-targeting prostate cancer epithelium and bone stroma by human osteonectin-promoter-mediated suicide gene therapy effectively inhibits androgen-independent prostate cancer growth. PLoS One 11(4):e0153350
Acknowledgement
This work was financially supported in part by the Ministry of Science and Technology in Taiwan (Grant No. 106-2320-B-038-055, 106-2320-B-038-056 and 107-2113-M-038-057), and the “TMU Research Center of Cancer Translational Medicine” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Hsiao, WC., Sung, SY., Chung, L.W.K., Hsieh, CL. (2019). Osteonectin Promoter-Mediated Suicide Gene Therapy of Prostate Cancer. In: Düzgüneş, N. (eds) Suicide Gene Therapy. Methods in Molecular Biology, vol 1895. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8922-5_3
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8922-5_3
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8921-8
Online ISBN: 978-1-4939-8922-5
eBook Packages: Springer Protocols